Sunzen Biotech Acquires Remaining Ecolite and Yanming Equity for RM24m
Sunzen Biotech Acquires Remaining Ecolite and Yanming Equity for RM24m
Sunzen Biotech proposes the acquisition of the remaining 30% equity in Ecolite Biotech and Yanming Resources for a total of RM24 million, to be satisfied through the issuance of approximately 73.22 million new ordinary shares at an issue price of RM0.295 per share.
Sunzen Biotech提議收購Ecolite生物技術和炎明資源剩餘的30％股權，總額爲2400萬令吉，將通過以每股0.295令吉的發行價格發行約7,322萬股新普通股來實現。
The acquisition aims to enhance Sunzen's position in traditional Chinese medicines and herbal health foods, contributing positively to its financial performance.
此次收購旨在提高Sunzen在中藥和草藥健康食品領域的地位，爲其財務業績做出積極貢獻。
The proposed transaction allows Sunzen to fully consolidate the financial results of Ecolite Group, and the issuance of new shares helps conserve cash for working capital and operational needs.
擬議的交易使Sunzen能夠全面整合Ecolite集團的財務業績，而新股的發行有助於節省現金以滿足營運資金和運營需求。
Sunzen's shares dip 3.33% to 29 sen today, with a market cap at RM209 million.
Sunzen的股價今天下跌3.33％，至29仙，市值爲 RM209 百萬。
譯文內容由第三人軟體翻譯。